Receive our newsletter – data, insights and analysis delivered to you
July 5, 2009

New Deep Vein Thrombosis Drug Moves to Phase II Testing

ThromboGenics NV and BioInvent International have begun enrolling patients in a Phase II trial of TB-402, a long-acting anticoagulant being developed for the prevention of deep vein thrombosis (DVT). The companies agreed to move ahead with trials after the external efficacy and safety mon

By cms admin

ThromboGenics NV and BioInvent International have begun enrolling patients in a Phase II trial of TB-402, a long-acting anticoagulant being developed for the prevention of deep vein thrombosis (DVT).

The companies agreed to move ahead with trials after the external efficacy and safety monitoring board gave unanimous approval to proceed using a higher dose of TB-402.

The Phase II trial is an active (enoxaparin)-controlled, dose-escalating, multicentre, prospective, randomised, open label trial to evaluate TB-402 for the prophylaxis of DVT after knee surgery.

The study will assess the safety and efficacy of three escalating doses of TB-402, given as a single intravenous bolus injection post knee replacement surgery.

TB-402 is a recombinant human monoclonal antibody that partially inhibits Factor VIII, a key component of the coagulation cascade to reduce the risk of undesirable bleeding events, and the need for patient monitoring.

In addition, TB-402 is a long-acting agent, which means it could be given as a single dose after surgery to prevent the development of DVT as opposed to all current anticoagulant treatment options, which require daily treatment for up to several weeks.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

The study will enrol a total of 300 patients across 36 centres, mainly in Europe.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU